

Rezlidhia (olutasidenib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
important for the review (e		, , ,	ny additional documentation that is request). Information contained in	
			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:		-		
CITY:		STATE: ZIP	STATE: ZIP CODE:	
PATIENT INSURANCE ID N	UMBER:			
IF YOU ARE NOT THE PATIENT OR THE PRE FOLLOWING LINK: HTTPS://MAGELLANRX	EIGHT (IN/CM): WE SCRIBER, YOU WILL NEED TO SUBMIT A PHI D C.COM/MEMBER/EXTERNAL/COMMERCIAL/CO EPRESENTATIVE (IF APPLICABI ATIVE'S PHONE NUMBER:	ISCLOSURE AUTHORIZATION FORM WITD MMON/DOC/EN-US/PHI DISCLOSURE	TH THIS REQUEST WHICH CAN BE FOUND AT THE AUTHORIZATION.PDF	
PRESCRIBER INFORMATION	ON			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
		l		
MEDICATION OR MEDICA	AL DISPENSING INFORMATIOI	V		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
ALEXACELLES A SYC		THERAPY/REFILLS:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (S Continued on next page.	DELCIFIC DATES).			



Page 1 of 3



Rezlidhia (olutasidenib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
	YOTHER MEDICATIONS FOR THIS COND	OITION? YES (if yes, complete			
below) NO					
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
□ Acute myeloid leukemia (AML)					
□ Other diagnosis:ICD-10					
2 DECLUDED CUNICAL INFORMATION	INDICASE DROVIDE ALL DELEVANT CLINIC	CALINICORMATION TO SURDORT A			
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Clinical Information:					
Is the drug going to be used in conjunction with a clinical trial? Yes No					
Initial Request:					
Is prescriber an oncologist or hematologist? Yes No					
•	sed or refractory acute myeloid leuken	nia (AML)? Yes No Please submit			
documentation.					
Does patient have a susceptible IDH1 mutation? Yes No Please submit documentation.					
Does patient have a susceptible 1D111	matation: 1103 1100 Flease subline do	cumentation.			
Does patient have symptomatic centr	al nervous system (CNS) metastases or	other tumor location (such as spinal			
· · · · · · · · · · · · · · · · · · ·	mass, uncontrolled painful lesion, bone	The state of the s			
therapeutic intervention, palliative care, surgery or radiation therapy? Yes No Please submit documentation.					
Renewal Request:					
Is patient continuing to demonstrate a positive clinical response? ☐ Yes ☐ No <i>Please submit documentation</i> .					
Are there any other comments, diagn	oses, symptoms, medications tried or fa	niled, and/or any other information the			
physician feels is important to this rev		,			
*Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required					
information is received.					
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that					
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical					
intormation necessary to verify the acc	uracy of the information reported on thi	is torm.			
Prescriber Signature or Electronic L.D.	Vorification:	Date:			
	v=: 410111	DATE.			





Rezlidhia (olutasidenib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:

MEMBER'S FIRST NAME:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn:CP-4201 P.O.Box 64811 St Paul, MN 55164-0811

Phone: 877-228-7909

